Polyneuron: Polyneuron Raises Additional CHF 14M; Expands Series A to CHF 36.5M

Polyneuron Pharmaceuticals AG, a Basel, Switzerland-based clinical stage developer of a new class of antigen-specific polymers for the treatment of patients with serious autoimmune diseases, raised a CHF 14m extension of the Series A, bringing the total to CHF 36.5m. HBM Healthcare Investments has joined the consortium of investors in the Series A, led by [...] The post Polyneuron Raises Additional CHF 14M; Expands Series A to CHF 36.5M appeared first on FinSMEs.